In order to clarify the structure and the peptide-presentation characteristics of the equine major histocompatibility complex (MHC) class I molecule, a complex of equine MHC class I molecule (ELA-A1 haplotype, 7-6 allele) with mouse 2 -microglobulin and the cytotoxic T lymphocyte (CTL) epitope Env-RW12 (RVEDVTNTAEYW) derived from equine infectious anaemia virus (EIAV) envelope protein (residues 195-206) was refolded and crystallized. The crystal, which belonged to space group P2 1 , diffracted to 2.3 Å resolution and had unitcell parameters a = 82.5, b = 71.4, c = 99.8 Å , = 102.9 . The crystal structure contained two molecules in the asymmetric unit. These results should help to determine the first equine MHC class I molecule structure presenting an EIAV CTL epitope.
Introduction
Major histocompatibility complex (MHC) class I molecules are glycoproteins which play a crucial role in the processes of cellular immunity (Yewdell et al., 2003) . Antigenic peptides derived from pathogens are specifically presented by MHC class I molecules and subsequently recognized by T-cell receptors (TCRs) on CD8 + T cells (Garboczi et al., 1996) . This process was not well visualized until the first structure of an MHC molecule was determined by Wiley and coworkers in 1987 (Bjorkman et al., 1987) . Three essential components compose an MHC class I complex: a membrane-anchored heavy chain with extremely diverse polymorphism (including external domains 1, 2 and 3), 2 -microglobulin (2m) and a short antigenic peptide (usually 8-12 residues) which is bound in the cleft formed by the 1 and 2 domains of the heavy chain termed the peptide-binding groove (Achour et al., 1998) . To date, studies of MHC class I molecules have mainly focused on those from human and mouse (Liu et al., 2010; Turner et al., 2005) . The features of equine MHC class I molecules remain poorly explored. The equine MHC class I molecule termed equine leukocyte antigen (ELA) is localized to positions q14-q22 on chromosome 20 (Ansari et al., 1988) . Approximately 15 ELA-A haplotypes of equine MHC class I molecules have been defined through serological assays (Lazary et al., 1988) . At least three loci may exist according to gene, serological and family studies (Chung et al., 2003) . However, the structure of the equine MHC class I molecule remains unclear.
Equine infectious anaemia virus (EIAV) is a macrophagetropic lentivirus that causes persistent infections in horses (Mealey et al., 2005) . Horses infected by the virus can develop recurrent febrile episodes and undergo plasma viraemia. Interestingly, in contrast to other lentiviral infections, most EIAV-infected horses can eventually control the disease process and become perpetual inapparent carriers (Mealey et al., 2006) . It has been proved that CTL plays an important role in eliminating the virus (Mealey et al., 2003) . In the 1970s, an EIAV donkey-leukocyte attenuated vaccine was developed in China and is the only effective vaccine to be developed against a lentivirus (Cohen, 2004) . Therefore, determination of the equine MHC class I complex structure will help in understanding the mechanism of immune response towards EIAV and might shed light on a lentiviral vaccine strategy. In this article, utilizing in vitro refolding and crys-# 2012 International Union of Crystallography All rights reserved tallization-condition screening, the equine major histocompatibility complex (ELA) class I molecule was successfully crystallized, making it possible to define the structure of the ELA-A1 haplotype 7-6 molecule (ELA-A1*7-6) complexed with an EIAV CTL epitope.
Materials and methods
2.1. Preparation of ELA-A1*7-6 and b2m proteins
The extracellular domain of the ELA-A1 haplotype 7-6 allele coding for 274 amino acids (GenBank accession No. AY225155) was synthesized by Beijing Sunbiotech Co. Ltd and ligated into cloning vector pMD18-T [Takara Biotechnology (Dalian) Co. Ltd]. For convenience of cloning, NdeI and XhoI restriction sites were added to the termini. After digesting the pMD18-T vector with NdeI and XhoI for about 10 h, the target 7-6 gene was recovered and inserted into the prokaryotic expression vector pET21a(+) (Novagen Merck KGaA, Darmstadt, Germany). The prokaryotic expression vector pET21a(+) containing the mouse 2m (m2m) gene had previously been constructed by our group (Li et al., 2011) . The two recombinant plasmids were transformed into Escherichia coli strain BL21 (DE3) and the proteins were both expressed as inclusion bodies. The process of extracting inclusion bodies was carried out as follows (Zhang et al., 2010) . The expression strain was inoculated into 2 l Luria-Bertani medium (LB) at 310 K. When the OD 600 value reached 0.6, isopropyl -d-1-thiogalactopyranoside (IPTG) was added to the LB medium to a final concentration of 1 mM to induce protein expression. 5 h later, the bacteria were harvested, lysed and centrifugated for 10 min at 11 000 rev min
À1
. The precipitate was then washed three times with a solution consisting of 1 mM EDTA, 1 mM DTT, 20 mM Tris-HCl, 100 mM NaCl, 0.5% Triton X-100. Finally, the inclusion bodies were dissolved in guanidinium chloride buffer [6 M guanidinium chloride, 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 mM NaCl, 10%(v/v) glycerine, 10 mM DTT] to a protein concentration of 30 mg ml À1 .
ELA-A1*7-6 complex preparation
The complex was prepared as previously described by Garboczi et al. (1996) with some modifications introduced in our laboratory (Zhang et al., 2010) . Briefly, 1 ml m2m protein solution was added to refolding buffer (100 mM Tris pH 8.0, 400 mM l-Arg, 2 mM EDTA, 5 mM GSH, 0.5 mM GSSG) using the gradual solution method at 277 K. After about 8 h, the peptide Env-RW12 (about 5 mg) was dissolved in dimethyl sulfoxide (DMSO) and added to the solution. Half an hour later, a 3 ml solution of the equine MHC I heavy chain was added dropwise to the refolding buffer. After incubation at 277 K for a further 8 h, the solution was concentrated and purified by chromatography on a Superdex 200 16/60 HiLoad size-exclusion column (GE Healthcare, USA) followed by Resource Q anionexchange chromatography (GE Healthcare).
Crystallization of the ELA-A1*7-6 complex
The purified protein (44 kDa) was dialyzed against crystallization buffer (50 mM NaCl, 20 mM Tris-HCl pH 8.0), transferred into centrifugal filter devices with a nominal molecular-weight limit of 10 kDa (Millipore Corporation, USA) and centrifuged at 4000g for approximately 30 min. The concentration of protein in the filtrate was then measured using the BCA Protein Assay Kit (Novagen, USA). Finally, the protein was diluted to concentrations of 6 and 12 mg ml À1 for crystallization. Crystallization trials were carried out using the Index kit (Hampton Research, Laguna Hills, California, USA) at 277 and 291 K by the hanging-drop method (Li et al., 2011) . Two drops containing equal volumes of protein solution (at 6 and 12 mg ml À1 ) and reservoir crystallization buffer (1 ml each) were placed over a well containing 150 ml reservoir solution in a VDX plate (Hampton Research). The best crystals were obtained in 5-7 d using Index solution No. 59 [0.02 M magnesium chloride hexahydrate, 0.1 M HEPES pH 7.5, 22%(w/v) poly(acrylic acid) sodium salt 5100] at 277 K.
Data collection and processing
Data collection from the crystal was carried out using a Rigaku MicroMax-007 rotating-anode X-ray generator operated at 40 kVand 20 mA (Cu K; = 1.5418 Å ). The crystal was first immersed in reservoir solution containing 20% glycerol for a few seconds and then flash-cooled in liquid nitrogen. Diffraction data were collected to 2.3 Å resolution and were indexed and scaled using DENZO and the HKL-2000 software package (Otwinowski & Minor, 1997 Elution profiles of purification of the refolded equine MHC I complex (ELA-A1*7-6, mouse 2m and EIAV Env-RW12 epitope) by Superdex 200 16/60 HiLoad gel-filtration and Resource Q anion-exchange chromatography (GE Healthcare). (a) Gel-filtration profile of the refolded products. Peak 1 contains aggregated heavy chain, peak 2 contains the correctly refolded complex (44 kDa) and peak 3 contains the abundant 2m. Insert: reduced SDS-PAGE gel (15%) of the corresponding purified protein from each peak. Lane M contains molecularweight markers (labelled in kDa). (b) Results of further purification of the refolded complex by anion-exchange chromatography. The complex was eluted at an NaCl concentration of 19.0-22.5%. Insert: reduced SDS-PAGE gel (15%) of protein from the peak.
Comparison of the ELA-A1*7-6 sequence to those of other MHC class I molecules
Sequence alignment was performed using DNAMAN v.5.5.2 (Raiola et al., 2004) . The accession numbers of the sequences used are as follows: ELA-A1*7-6, AY225155; ELA-N*01401, ADK02607; SLA-1*0101, FJ952938; BoLA-N*01301, CAA56909; H-2Kb, V00746; Mamu-A*02, AAA96050; HLA-B*3501, 1A1_N.
Results and discussion
ELA-A1*7-6 was refolded together with m2m and the Env-RW12 epitope and resulted in yields of MHC class I molecule of about 10-15%. The complex was initially purified by Superdex 200 16/60 HiLoad size-exclusion chromatography (Fig. 1a) . The elution profile shows three peaks corresponding to the refolded complex (44 kDa; peak 2), non-native aggregated products (peak 1) and redundant 2m (peak 3). The refolded complex was then collected and purified by Resource Q anion-exchange chromatography (Fig. 1b) . The purity was sufficient for protein crystallization. SDS-PAGE was used to confirm the presence of the refolded complex and showed two bands corresponding to the molecular weights of the heavy chain (32 kDa) and m2m (12 kDa).
Crystallization trials were initially carried out using the Index kit (Hampton Research, America) at a temperature of 291 K. Protein crystals appeared in many conditions and grew quickly, but failed to diffract. We performed the trials again at a temperature of 277 K. The best crystals (Fig. 2) , and diffracted to 2.3 Å resolution (Fig. 3) . The Matthews coefficient V M was calculated to be about 3.21 Å 3 Da
À1
, corresponding to 61.67% solvent content (Kantardjieff & Rupp, 2003; Matthews, 1968) . Other selected data are listed in Kantardjieff & Rupp (2003) . ‡ R merge = P hkl P i jI i ðhklÞ À hIðhklÞij= P hkl P i I i ðhklÞ, where I i (hkl) is the observed intensity and hI(hkl)i is the average intensity from multiple measurements (Diederichs & Karplus, 1997) . Figure 3 Diffraction pattern of the equine MHC class I molecule. The high-resolution spots are highlighted by the enlargement. Table 1 . It is obvious that the temperature affects not only the shape and growth rate of the crystals but also the quality.
The results of the sequence alignment of MHC class I molecules are shown in Fig. 4 . Both the ELA 7-6 and 01401 alleles belong to the A1 haplotype and share 97.8% identity. ELA-A1*7-6 has 71.53, 75.91 and 77.37% identity to MHC class I molecules from mouse (H-2Kb), swine (SLA-1*0101) and cattle (BoLA-N*01301) and shares 82.48 and 84.67% identity with those from human (HLA-B*3501) and monkey (Mamu-A*02). From the results, we can see that the equine MHC class I molecule has higher homology to those from primates than to those from other animals.
Although the number of horses worldwide is decreasing, studies of their immune system are still significant. As the infection of horses with EIAV is one of the models for studying lentiviral control, the first equine MHC I molecule structure will clarify the characteristics of the horse MHC I molecule and provide information for lentiviral vaccine design.
